CHARITY COMMISSION FOR ENGLAND AND WALES Independent examiner's report on the accounts Section A Independent Examlner's Report Report to the truste&sl members of Charity Name Chronic Lymphocytic Leukaemia Support Association UK (CLLSA) On accounts for the year ended 31 De¢ember 2024 Charity no (if any} 1178482 Set out on pages Iremember lo include the psge nutnbers of addilion815heelsl I report to the truslees on my examination ofthe a¢counts of the above charity {'the Trust") for the year ended 31112124. Responsibilities and As the charity truslees of the Trust, you are responsible for the preparation basis of report of the accounts in accordance with the requirements of the Charities Act 2011 flhe Act"). I report in respect of my examination of the Trust's accounts carried out und&r section 145 of the 2011 Act and in carrying out my examination, I have followed the applicable Directions given by the Charity Commission under seGlion 145(5){bl of the Act. I have completed my examination. I confirm that no material matters have come to my attention {other than that disclosed below ') in connection with the examination which gives me cause to believe that in, any material respect- accounting records were not kept in accordance with seotion 130 of the Act or the accounts do nol accord with the accounting records Independent examiner's statement I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in order to enable a proper understanding of the accounts lo be reached. Please delete Ihe words in the brackets if they do not apply. Slgned: Date: Name: Andy Davis FCA Relevant professional quallficatlonls) or body (If any): Institute of Chartered Accountants in England and Wales {ICAEW) Address: The Old Post Office, 41-43 Market Place Chippenham SN15 3HR IER October 2018
Section B Disclosure Only complete if the examiner needs to highlight matlers of concern (see CC32. Independent examination of charity accounts.. directions and guidance for examiners). Give here brief details of any items that the examiner wishes to disclose. IER Octobor 2018
CHARITY COMMISSION FOR ENGtAND AND WALES Chronlc LymphoGyll¢ Leukagmts Support 550ClIon U 1178482 Receipts and payments accounts CC16a For thè p•rlod from 01110rI023 3111V2024 Section A Receipts and payments Unre5trfcted fund• tOlh• n•aig11 ReslriGted fund• Endowment funds Total fund* La¥tyear toth• nwi•¥t£ toth•n•arttt£ 10 lh• n•ir••t£ toth• nMMtstÉ Al Rè¢èl t$ 138.12Y IJO 127 Grenlg 928 2.194 4#2 6.926 Bonk •nd d• ftlnt¢re•t Sub total{Gmss Incom8 ftsr AR) 180,140 116M47 A2 A8S•t and Inve¥tment sAIo•, (#•• table 931 931 Sub total •Ji 931 16t.771 80,000 221.yll 116,047 A3Pa ments SupportwJFk Adm5nhlièLk)n FundtaWng 69,667 112.637 37,115 17.856 Sub lolal 151.105 ¢o.ooo 211.15$ 166,30B A4 A•8•t and Invostmant 49.367 Sub totsl 49.367 Toial payments 1151,111J 60,000 211.1 217.676 Net of recelptsl{paymontsJ A5 Tran•l•rs b•lwo•n fund• A6 Ca¥h fund¥ last ygar •nd Cash funds th18 yèarond 10.618 10.616 101,628 278,86T 287A83 278,867 287,4eJ 378,496 276,867 CCXX R1 at¢ounls (88) 07105R025
Seclion B Stalemenl ol assets and liabililies at the end ot Ihe period H•stiielgd lynd$ 19 n••rts1 £ Gnoowmont funds lunds B1 Cash lund Bankéi¢ 2IS.B1S tyotsnniin'i IA70 Tolal casl? lundj 207.489 &.t41Thb'. Unigslrletèd Iynd? £nilowmot)I tund 1¢ nv•éal t lund$ io n?•rÈsi t B2 Other monetttry ossets 920
ffTh)Id trxpMr.r.'. 625 10 whlt asttl bolon Co$i1¢gll•na B3 Inveslmenl 3988ts FuDdto whlch ••ei b•iDn Coll iopllonpl) -loLllontsiL_ B4 Assèts rfrtalnèd IOT the eharlly s own use Fufid lo whlth Whvn duo lopInlI BS Llabllltlets Pfiiil Daio o. approval PE<60 i>/h /2)-1 c.xx H? AC{.'IIUll.'s ISS..
CHARITY COMMISSION FOR ENGLAND AND WALES Tru¥t9e$' annual report Ilncludlng DlreGto.rs' reportl forthe perlod from: 01 October 2023 to: 31 December 2024 Charlty name: Chronlc Lymphoeytlc Leukaemla Support Assoclatlon UK (CLLSA) Charlty reglstratlon number: 1178482 Objectlves and actlvlties SORP réferènca Pa(a 1.17 Summary of Ihe purp08es of th8 charity as 881 oul in ils governing document 1. To r91ieve ?lthne66 and lo pT¢serve and protect health by providing support to chronic tymphocytic18uka8mla (CLLI p2118nl8 and thelr ttArér8. ICLL inclurtas similar f8laled condition5 such as SLL). 2. To advanc& publlc educallon In CLL related matlors primarily in the UK thiough publi¢ation5 and Ihe inlernel. 3. To promo1& and oupport scienlrfiG resoarth into the Ifealm8nt and car8 of all CLL patients. Summaiy of Ihe main aclivilie$ in relation lo those Pufptrses for thè public b8n8fil, in partieJJlar. the activili&s, proje¢l8 or services idenlrfied in the accounts. Pgra 1.17 and 1.19 1. The provision ol up to date and 8ccessibl& information about CLL, thè rangè of treatments currèntly 8vailablo and the lal&81 r9s8arch into the cafe and Ire8lm9nl of CLL, through the Charity's websila, webinar8, member conferences, publl¢albns and 4 telephone hglplin8. 2. The d&velopment of opportunities lo share underslandlnu and personal experience by bringing CLL palienls logelher. and by crealing mutual support groups and nerks. 3. Acllng as a vol¢e for CLL patients. representing Ihelr Interests wilh the pharmar£ullcal Industry, cllnlclans, NHS, cancer cmre pollcy and drug regulatory aulharille5, funding and COEnmissioning groups and Govemmenl. 4. Th8 promollon ofan awareness of CLLSA, together with ils role amongst health care providers and decision makers, provideis of non- healthcarè PTodutttS and Sérvicès. olher blood cancer patient groups and Iho wider wblic.
81818m8nt confim)ing wh&thar thè Irusle&s havé had règard lo th8 guidanrA issued by the Charity Commisslon on publi¢ b&nefil PaT8 I.q8 In undertaking Ihfrso aclivilies. lh8 Trus18es cnfIrM that Ihgy have had ¥egard to the guidance issued by th6 Charity Commission on th9 mall8r of publ{¢ banelil. Addltlonal Information loptlonal) You may choose to Include further sialomonls where relevant aboul.. SORP i•f¢rgnGg Para 1.38 Pollcy on grant making Policy on sts¢ial investment Including progr8rn related invoslmgnl Para 1.38 Contribulion made by volunleors Para 1.3B Other Achlevements and performance Summaryofthe main achievements of th8 charity, Idenlifying the difference Ihg charrty's work has mada lo the ircumsl8nces ol ils beneficiaries and any wid8r beneli15 to socigly as a whole. Para 1.20 Every mèmbor of the Board of Trustees ha5 bgon ffèelÉd personally by CLL, 8iiher as a pallanl or Ihrouoh a close personal rélationship with patient, and ac¢or(Jingly is w811 ploced to judge the nèeds ¢f GLL pgtienls and Ihelr supporte With the assislanc of d8dlealed part Ilme members Of staff, gvery individual Trustee is Ith directly and heavily involved in the delivery of Ih support services that the Charlly has lo.offer. As11 h8s moved on Irom Ihe Immediate ehalleng8s of Ihe Covld.19 pandemlc. the Charfty has.. 1. ReinlroduGed In-person member conf8fence8 as well as continuing lo provldo onlin8 webinar piesenlalions. Th&s8 presenlalions conlinu8d lo be fronted by many of the legding expèrts in the field of the Ifealmenl of CLL. 2. Continued 118 ¢106e ¢ollaboralion wila th$ UK CLL Forum. thus helping th8 Forum lo brid9a th9 gap baen Scientists. Clinicians and Palients. 3. Continugd ils work with the Blood Can¢er Allianc8 and with Cfjn¢er52 lo promole lh8 Interests of Ihoso sufferir*J from blood cancers 8nor81, and from CLL In 8rtlculor.
- Conlinuod with the development and roll out of ils Support ACT PTogramme, offering us8rs access to guidanog and support lo help improvo the well-being of CLL pallenls and their immediatè supportors. S. Conlinuod lo mainl8in a lel8phon8 h8lplinè sérvice that is available to offer Immediate Support and ouid8ncg 10 CLL palien18 and the 5UPPOrters,
- Conllnued lo partlclp818 in p&thering arrangements wilh major pharmaceutical ompanie5 designed lo offer those compani88 kèy inslghls Into the way In whlch Irealmenls for CLL impact on the lives and wellbefng of patients.
- Continued lo benefit from donations and fundralslng aclivilie3 that were underlaken by its supporters. 2024 was the 20th Anniversary of CLL Support and our Challeng8 20 encouraged members lo undortake activiliès 8nd raiso furKfs for th9 Charily
- Continued 10 benafil from fvnding provlded by th8 pharmacautiC81 inthsty. Additional Infomiation (optionall You may choos8 to in¢lud$ further Slalgments where rebvant aboul.. Achi8V8menl8 against objectlves gel Para 1.41 Perforrnance ol fundrai8lng aclivltigs auainst objgGtives sel P8r4 1.41
Invgslment performance agalnsl objectives Para q.41 Olher
Flnancial review Revlew of thè charitS financial position at the end ol the pgrlod P8f8 1.21 Statement explaining the policy for holding reservès Staling why they are hèld Para 1.22 Thè Charity aims lo maintain total reserv¢s Ihal are no more than 18 months ol Ihe anlicipaled normal18vel of amual runnlno cosl8. An amount which is between 12 and 15 month5, planned expendllure Is held In the fom of c8sh reseeS to en8uie both conliryjèd finanttial 58curily and to provtde lor conliryenci8B. In delemiining these flgure8, Ihg Trustee¥ have con8idereiS thè need lo hold back some funds as résoNe$, using th8 categories 881 out In the Charily Commission Guidanc£ Ooeumenl CC19'. Charity reserves.- l)ulldlng reslli8nce. Amounl of reserves held Para 1.22 At lh6 end of th& period the Charily held r¢serve8 01 £342,001 Raasons for holdlng zero reserves Para 1.22 NIA Delalls of fund mèlerially in doficil Paia 1.24 Noné Explanalic)n ol any uncertainties about Ihe charily CA)nlinuing as a golng concern Pjra 1.23 None Ir) the immediately foroseaable future Addltlonal Infomiatlon loptlonal) You may ¢hoo89 to include further sts19mgnl$ where Televanl about.. The ch8rily's principal sourc9$ of fund8 (Indudln9 ariy fundraigingl Para 1.47 Investmant policy Bnd obleGlives including any social Inveslmenl policy adoptèd Para 1.46 A descriplion of the principal risks facing the charity Para 1.46 Other Structure, governanco and management D8Bcriplion of charity'$ Irusls: Type of governing doGument'. Para 1.25 Tru81 De6d dated 22tvJ May 2018 How 18 the charily conslrtul8d? Para 1.25 Chafilable Incorporated Organi8alion
Trustee selgction melho includino del8ils of any cKnslilulional provision$ Para 1.25 Eleclion by a majorily ol the 8xisling Trus18ès Addluonal Infomiatlon (optlonall You may choose to Inolude furlher slalemenl8 %there relevant about.. PoliGies 2nd proGedure5 aijopled for the Inductlon and training of Iru51ees Para 1.51 Th8 charily's organisalional slfuolure and any wider nelwork wilh which Ihe charily works Para 1.51 Relationship with any relaled P8rtièS Para 1.51 Other Reference and admlnlstratlve detalls Charity name Chronlc Lymphocytlo Leukaomla Support AB60Glatlon UK {CLLSAI Other nam8 th8 charity us88 {1) CLL Support 1111 CLL Support As60clatlon Reglstered ch8rity number 1178482 Chadly's prlnclpal address Su5te 112- 8 The Brldge, Chlppenham. Wllt8. SN16 1FY Name8 of the Gharlty tru$t9e8 who manage tho charlty Name ofpèrson lor body) •ntllèd to appolnt tru8tee Ifan TNsts• nam• Offloo111 any) DateB acted If not for whole year Allen, Poler G8rdom, Brlan Granl, Norah Greensmyth, John Holland, Anthèa Linds£y, Hilary Mercer, Frank 10.06.2024 to 31.12.2024 01.10.202310 18.10.2023 Chair Treasurer to 16.10. 2023 01.10.2023 to 16.10.2023 Wiegman, Gail steffi Sutters Debra Yales 01.10.2023 to 19.02.2024 10 11 Steven Abraham8 01.10.202310 19.08.2024
12 Andrew Taylor Trea8ur8r from 16.10.2023 01.10.2023 to 29.11.2024 Cor orate Irustees- names of the directors at the date the re Dlrector name rtwasa roved NIA Name of tTUStees holding title to properly belonging to the charily Tnjstee name Daté8 4et•d if not for wholo NIA Funds held as custodian trustees on behalf of others Descfiplion of the assets held In this CapatY Nono Name and objects of th& charily on whose behalf Ihe assèts are hold and how this falls within the custodian charily's oble¢ts NIA D8t2ils of arrangements for safe ¢ustody and segiegalion (Jr such as8$ls from Ihe charit$ own assets NIA Addltsonal infomiation loptionall Namgs and addfessos of adv15er8 (opuonal Infomiatlon) of advlser Name Addr86S Name of chlof •x•cutlve or names of senlor Staff members {optlonal Informatlon) Exemptions from disclosure Reason for non-disclo$ur8 of key p&rsonnel details Declaratlons
abtsv Th•lrn•t•M d0 Ihal th•y hw• approv th• tru•tO••' f•PDrt Ilndudlnq dlrnvtw•' r•port) on b•hAII •1 lh• ob•Oty Inj•1•A]rO 8lgnAtur•(8) Full namo(81 Po•ltlon Hllary Lindsay PeterAllon Chelr of TN8tge8 Tru#tee